Avanir Pharmaceuticals

Insiders may sell shares for any number of reasons, but there is really only one reason insiders buy shares of a company -- they believe the stock price will move higher and they want to profit from it. Pullbacks and sell-offs provide a perfect opportunity for investors who have faith in a company...

Jefferies initiated coverage of Cisco Systems (NASDAQ: CSCO) with a Hold rating. At the same time, Jefferies put its price target on the company's stock to $15.75. In a research report published today, Jefferies states, "We believe it's too early for investors to commit to the stock as we're still...

Jefferies is assuming coverage of Avanir Pharmaceuticals (NASDAQ: AVNR) with a $3.50 price target and a Hold rating. “AVNR markets Nuedexta, a low-dose combination of dextromethorphan and quinidine, for pseudobulbar affect, a disorder of laughing or crying that can accompany neurological disease...

Wedbush is out with its report today on Avanir Pharmaceuticals (NASDAQ: AVNR), maintaining Outperform. In a note to clients, Wedbush writes, "AVNR reported Q2 NUEDEXTA revenues of $505 thousand and EPS of ($0.12), vs. our estimate of $404 thousand, ($0.14) and the Street's ~0.9-1 million, ($0.11...